Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension

Thorax

Volumn 54, Issue 2, 1999, Pages 161-168

  Egermayer, Paul ^a   Town, G Ian ^a   Peacock, Andrew J ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ACUTE DISEASE; CHRONIC DISEASE; HUMAN; NEUROSECRETORY CELL; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONIN BLOOD LEVEL;

EID: 0032991465     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2.161     Document Type: Review

References (186)

1. 1 Rounds S, Hill NS. Pulmonary hypertensive diseases. Chest 1984;85:397-405.
2. 2 Alpert JS, Irwin RS, Dalen JE. Pulmonary hypertension. Dis Mon 1981;5:1-39.
3. 3 Reid LM. Structure and function in pulmonary hypertension. Chest 1986;89:279-88.
4. 4 Chouat A, Weitzenblum E, Higgenbottam T. The rule of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356-63.
5. 5 Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associatied with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997;28:434-42.
6. 6 Rubin LJ. Introduction. In: Rubin LJ, ed. Pulmonary heart disease. Boston: Martinus Nijhoff, 1984: 1-10.
7. 7 Cooper R, Ghali J, Simmons BE, et al. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest 1991;99:112-20.
8. 8 Draughn D, Morris DM. Sustained pulmonary hypertension in surgical patients. Am Surg 1993;59:346-9.
9. 9 Keller CA, Shepard JW, Chun DS, et al. Pulmonary hypertension in chronic obstructive pulmonary disease. Multivariate analysis. Chest 1986;90:185-92.
10. 10 Bitterman PB, Henke CA. Fibroproliferative disorders. Chest 1991;99:81-6S.
11. 11 Hart CM, Block ER. Lung serotonin metabolism. Clin Chest Med 1989;10:59-70.
12. 12 Perry RR, Vinik AI. Endocrine tumors of the GI tract. Annu Rev Med 1996;47:59-62.
13. 13 Lockhart A. Pulmonary arterial hypertension in portal hypertension. Clin Gastroenterol 1985;14:123-38.
14. 14 Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.
15. 15 Katz AI, Massry SG, Tikvah P. Arteriospasm after ergotamine tartrate in infectious hepatitis. Arch Intern Med 1966;118:62-4.
16. 16 Block ER, Stalcup A. Metabolic functions of the lung. Of what clinical relevance? Chest 1982;81:215-23.
17. 17 Boor PJ, Hysmith RM, Sanduja R. A role for a new vascular enzyme in the metabolism of xenobiotic amines. Circ Res 1990;66:249-52.
18. 18 Wiedemann HP, Mathay MA, Gillis CN. Pulmonary endothelial cell injury and altered lung metabolic function. Clin Chest Med 1990;11:723-36.
19. 19 Sole MJ, Drobac M, Schwartz L, et al. The extraction of circulating catecholamines by the lungs in normal man and in patients with pulmonary hypertension. Circulation 1979;60: 160-3.
20. 20 Johnson DA, Georgieff MK. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am Rev Respir Dis 1989;140:1807-12.
21. 21 Lauweryns JM, de Bock V, Guelinckx P, et al. Effects of unilateral hypoxia on neuroepithelial bodies in rabbit lungs. J Appl Physiol 1983;55:1665-8.
22. 22 Gosney J, Heath D, Smith P, et al. Pulmonary endocrine cells in pulmonary arterial disease. Arch Pathol Lab Med 1989;113:337-41.
23. 23 Madden BP, Gosney J, Coghlan JG, et al. Pretransplant clinicopathological correlation in end-stage primary pulmonary hypertension. Eur Respir J 1994;7:672-8.
24. 24 Breuer J, Georgaraki A, Seiverding L, et al. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Pediatr Cardiol 1996; 17:214-9.
25. 25 Schindler MB, Bohn DJ, Bryan AC, et al. Increased respiratory resistance and bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Am J Respir Crit Care Med 1995;152:1347-52.
26. 26 Keith I, Day R, Lemaire S, et al. Asbestos-induced fibrosis in rats: increase in lung mast cells and autacoid contents. Exp Lung Res 1987;13:311-27.
27. 27 Nakano T, Miyamoto K, Nishimura M, et al. Role of pulmonary intravascular macrophages in anti-platelet serum-induced pulmonary hypertension in sheep. Respir Physiol 1994;98:83-9.
28. 28 Jubelirer SJ. Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. Arch Intern Med 1991;151:1221-3.
29. 29 McGoon MD, Vanhoutte PM. Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin Invest 1984;74:828-33.
30. 30 Bennett JS, Kolodziej MA. Disorders of platelet function. Dis Mon 1992;28:577-631.
31. 31 Nakonechnicov S, Gabbasov Z, Chazova I, et al. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinol 1996;7:225-7.
32. 32 Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
33. 33 Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987;76: 1043-52.
34. 34 Schnader J, Schloo BL, Anderson W, et al. Chronic pulmonary hypertension in sheep: temporal progression of lesions. J Surg Res 1996;62:243-50.
35. 35 Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med 1996;239:17-34.
36. 36 Moore GW, Smith RR, Hutchins GM. Pulmonary artery atherosclerosis: correlation with systemic atherosclerosis and hypertensive pulmonary vascular disease. Arch Pathol Lab Med 1982;106:378-80.
37. 37 Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-54.
38. 38 Constanides P, Robinson M. Effects of vasoactive amines. Arch Pathol 1969;88:106-12.
39. 39 Moore LK, Burt JM. Gap function in vascular smooth muscle: influence of serotonin. Am J Physiol 1995;269: H1481-9.
40. 40 Heffner JE, Sahn SA, Repine JE. The role of platelets in the adult respiratory distress syndrome. Culprits or bystanders? Am Rev Respir Dis 1987;135:482-92.
41. 41 Comroe JH, van Lingen B, Stroud RC. Reflex and direct cardiopulmonary effects of 5 OH tryptamine (serotonin). Their possible role in pulmonary embolism and coronary thrombosis. Am J Physiol 1953;173:379-86.
42. 42 Reneman RS, van der Starre PJ. Serotonin and acute cardiovascular disorders. Cardiovasc Drugs Ther 1990; 4(Suppl 1):19-25.
43. 43 Brogden RN, Sorkin EM. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs 1990;40:903-49.
44. 44 Buckner CK, Dea D, Liberati N, et al. A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig. J Pharmacol Exp Ther 1991;257:26-34.
45. 45 Pakala R, Willerson JT, Benedict CR. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994;90: 1919-26.
46. 46 Hauck AJ, Edwards WD, Danielson GK, et al. Mitral and aortic valve disease associated with ergotamine therapy for migraine. Report of two cases and review of literature. Arch Pathol Lab Med 1990;114:62-4.
47. 47 Lee SL, Wang WW, Joseph PM, et al. Inhibitory effect of heparin on serotonin-induced hyperplasia and hypertrophy of smooth muscle cells. Am J Respir Cell Mol Biol 1997;17: 78-83.
48. 48 Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol 1997;272:L795-806.
49. 49 Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509.
50. 50 Campbell JH, Campbell GR. Vascular smooth muscle in culture and its relevance to the study of atherogenesis. In: Page C, Black J, eds. Airways and vascular remodelling in asthma and cardiovascular disease. London: Academic Press Harcourt Brace, 1994: 27-37.
51. 51 Rabinovitch M. Investigational approaches to pulmonary hypertension. Taxicol Pathol 1991;19:458-69.
52. 52 Scott PH, Peacock AJ. Cell signalling in pulmonary vascular cells: do not shoot the messenger! Thorax 1996;51:864-6.
53. 53 Kay JM, Keane PM, Suyama KL. Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p-chlorophenylalanine. Respiration 1985;47:48-56.
54. 54 Eddahibi S, Raffestin B, Pham I, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997;272:H1173-81.
55. 55 Gyermek L. Pharmacology of serotonin as related to anesthesia. J Clin Anesth 1996;8:402-25.
56. 56 Frishman WH, Huberfeld S, Okin S, et al. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol 1996;35:541-72.
57. 57 Zeiher AM, Schachinger V, Hohnloser SH, et al. Coronary atherosclerotic wall thickening and vascular reactivitiy in humans. Elevated hight-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525-32.
58. 58 Steyn DW, Odendaal HJ. Randomised controlled trial of ketanserin and asprin in prevention of pre-eclampsia. Lancet 1997;350:1267-71.
59. 59 Morcos NC, Purdy RE, Henry WL. Vasoreactivity in isolated perfused atherosclerotic human coronary arteries. Int J Tissue React 1988;10:159-67.
60. 60 McFadden EP, Clarke JG, Davies GJ, et al. Effect of intra-coronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991;324:648-54.
61. 61 Drouet L, Sollier BD, Ruton S, et al. Role of serotonin in arteriolar thrombosis and secondary vasospasm. J Cardiovasc Pharmacol 1990;16(Suppl 3):S49-53.
62. 62 Siegel G, Ruckborn K, Schnalke F, et al. Endothelial dysfunction in human atherosclerotic coronary arteries. Eur Heart J 1993;14(Suppl I):99-103.
63. 63 Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
64. 64 Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993;70: 537-41.
65. 65 Fristrom S, Airaksinen MM, Halmekoski J. Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivates. Acta Pharmacol Toxicol 1977;41:218-24.
66. 66 Naeije R, Maggiorini M, Delcroix M, et al. Effects of chronic dexfenfluramine treatment on pulmonary hemodynamics in dogs. Am J Respir Crit Care Med 1996;154:1347-50.
67. 67 Seiler KU, Wasserman O, Wensky H. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs: an experimental study in the isolated perfused rat lung. II. Fenfluramine, mazindol, mefenorex, phentermine and R800. Clin Exp Pharmacol Physiol 1976;3:323-30.
68. 68 Mielke H, Seiler KU, Stumpf U, et al. Relation between serotonin metabolism and pulmonary hypertension in rats following administration of various anorectic drugs. Z Kardiol 1973;62:1090-8.
69. 69 Weir EK, Reeve HL, Huang JM, et al. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary smooth muscle and cause pulmonary vasoconstriction. Circulation 1996;94:2216-20.
70. 70 Mills KC. Serotonin syndrome. A clinical update. Med Toxicol 1997;13:763-83.
71. 71 Collazos J, Martinez E, Fernandez A, et al. Acute, reversible pulmonary hypertension associated with cocaine use. Respir Med 1996;90:171-4.
72. 72 Booker PD, Evans C, Franks R. Comparison of the haemodynamic effects of dopamine and dobutamine in young children undergoing cardiac surgery. Br J Anaesth 1995;74: 419-23.
73. 73 Dukes MGG, ed. Meyler's side effects of drugs. Lausanne: Elsevier, 1996: 17.
74. 74 de Kerviler E, Tredaniel J, Revlon G, et al. Fluoxetin-induced pulmonary granulomatosis. Eur Respir J 1996;9: 615-7.
75. 75 Filterborg JA. Persistant pulmonary hypertension after lithium intoxication in the newborn. Eur J Pediatr 1982;138:321-3.
76. 76 Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993;104:614-16.
77. 77 Fujiwara M, Tobise K, Onodera S. Effects of methysergide on pulmonary circulation. Hokkaido J Med Sci 1983;58: 541-2.
78. 78 Radow SK, Nachamkin I, Morrow C, et al. Foreign body granulomatosis. Clinical and immunologic findings. Am Rev Respir Dis 1983;127:575-80.
79. 79 Van der Starre PJ, Solinas C. Ketanserin in the treatment of protamine-induced pulmonary hypertension. Texas Heart Inst J 1996;23:301-4.
80. 80 Voelkel NF. Appetite suppressants and pulmonary hypertension. Thorax 1997;52:563-7.
81. 81 Tazelaar HD, Myers JL, Drage CW, et al. Pulmonary diseases associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features. Chest 1990;97:1032-6.
82. 82 Farber HW, Falls R, Glauser FL. Transient pulmonary hypertension from the intravenous injection of crushed suspended pentazocine tablets. Chest 1981;80:178-82.
83. 83 Arnett EN, Battle WE, Russo JV, et al. Intravenous injection of talc-containing drugs intended for oral use. A cause of pulmonary granulomatosis and pulmonary hypertension. Am J Med 1976;60:711-8.
84. 84 Spah F, Kottman R, Grossner KD, et al. Effects of Urapidil in patients with mild pulmonary hypertension. Drugs 1990; 40(Suppl 4):69-70.
85. 85 Tornebrandt K, Eskilsson J, Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol 1986;9:13-9.
86. 86 Arora RR, Warner RR. Do indole marker predict carcinoid heart disease? Chest 1986;90:87-9.
87. 87 Lundin L, Oberg K, Landelius J, et al. Plasma atrial natriuretic peptide in carcinoid heart disease. Am J Cardiol 1989; 63:969-72.
88. 88 Jacobsen MB, Nitter-Hauge S, Bryde PE, et al. Cardiac manifestations of mid-gut carcinoid disease. Eur Heart J 1995;16:263-8.
89. 89 Robiolo PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterisation and echocardiography. Circulation 1995;92:790-5.
90. 90 Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8.
91. 91 Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut tumors. Surgery 1981;90:720-8.
92. 92 Gaudin PB, Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoploasms. A diagnostic clue and potential pitfall. Am J Surg Pathol 1995;19:642-52.
93. 93 Wilson DW, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992;22:307-25.
94. 94 Todrorovich-Hunter L, Dodo H, Ye C, et al. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared wtih infant rats with nonprogressive disease. Am Rev Respir Dis 1992;146:213-23.
95. 95 Kanai Y, Hori S, Tanaka T, et al. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993;27:1619-23.
96. 96 Roth RA, Ganey PE. Platelets and the puzzles of pulmonary pyrrolizidine poisoning. Toxicol Appl Pharmacol 1988;93: 463-71.
97. 97 Ganey PE, Sprugel KH, White SM, et al. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol 1988;255:H1165-72.
98. 98 Hilliker KS, Roth RA. Alteration of moncrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone. Br J Pharmacol 1984;82:375-80.
99. 99 Tanabe T, Furaya H, Kanemoto N, et al. Experimental study on monocrotaline induced pulmonary hypertensive rats. (1) Effect of long-term injection with immunosuppressants. Tokai J Exp Clin Med 1981;6:41-8.
100. 100 Langleben D, Carvalho AC, Reid LM. The platelet inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension. Am Rev Respir Dis 1986;133: 789-91.
101. 101 Hamilton WM, Nemir P. The humoral factor in pulmonary embolism. Arch Surg 1972;105:593-8.
102. 102 Smith G, Smith AN. The role of serotonin in experimental pulmonary embolism. Surg Gynecol Obstet 1955;101:691-9.
103. 103 Gurewich V, Cohen ML, Thomas DP. Humoral factors in massive pulmonary embolism: an experimental study. Am Heart J 1968;76:784-91.
104. 104 Gurewich V, Thomas D, Stein M, et al. Bronchoconstriction in the presence of pulmonary embolism. Circulation 1963;XXVII:329-45.
105. 105 Kawai A, Umeda A, Mori M, et al. Role of serotonin in impaired gas exchange during pulmonray embolism. Nippon Kyobu Shikkan Gakkai Zasshi 1995;33:947-55.
106. 111In-labelled platelet-specific monoclonal antibody, P256. Chest 1992;101:1597-601.
107. 107 Thomas DP, Gurewich V, Ashford P. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism. N Engl J Med 1966;274:953-6.
108. 108 Monreal M, Lafoz E, Casals A, et al. Platelet count and venous thromboembolism. A useful test for suspected pulmonary embolism. Chest 1991;100:1493-6.
109. 109 Williams GD, Westbrook KC, Campbell GS. Reflex pulmonary hypertension and systemic hypotension after microsphere pulmonary embolism: a myth. Am J Surg 1969;118:925-30.
110. 110 Onodera S. Pulmonary vasoconstrictor responses. Nippon Kyobu Shikkan Gakkai Zasshi 1992;30(Suppl):15-25.
111. 111 Mlczoch J, Tucker A, Weir EK, et al. Platelet-mediated hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition. Chest 1978;74:648-53.
112. 112 Huval WV, Mathieson MA, Stemp LI, et al. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism. Ann Surg 1983;197:220-5.
113. 113 Huet Y, Brun-Buisson C, Lemaire F, et al. Cardiopulmonary effects of ketanserin infusion in human pulmonary embolism. Am Rev Respir Dis 1987;135:114-7.
114. 2 receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985;7(Suppl 7):S64-6.
115. 115 Siegal T, Pfeiffer MR. Radiation-induced changes in the profile of spinal cord serotonin, prostoglandin synthesis, and vascular permeability. Int J Radiat Oncol Biol Phys 1995;31:57-64.
116. 116 Bremer K. 5 Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis. J Cancer Res Clin Oncol 1991;117:85-7.
117. 117 Peterson LM, Evans ML, Graham MM, et al. Vascular response to radiation injury in the rat lung. Radiat Res 1992;12:139-48.
118. 118 Gillette SM, Powers BE, Orton EC, et al. Early radiation response of the canine heart and lung. Radiat Res 1991;125:34-40.
119. 119 Tillman BF, Lloyd JE, Malcolm AW, et al. Unilateral radiation pneumonitis in sheep: physiological changes and bronchoalveolar lavage. J Appl Physiol 1989;66:1273-9.
120. 120 Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997;9: 55-60.
121. 121 Tomashefski JF, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983;112:112-26.
122. 122 Fowler AA, Hamman RF, Zerbe GO, et al. Adult respiratory distress syndrome. Prognosis after onset. Am Rev Respir Dis 1985;132:472-8.
123. 123 Bone RC, Francis PB, Pierce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;61:585-9.
124. 124 Carvalho AC, Quinn DA, De Marinis SM, et al. Platelet function in acute respiratory failure. Am J Haematol 1987; 25:377-88.
125. 125 Fein A, Lippmann H, Hotzman H, et al. The risks, incidence and prognosis of adult distress syndrome following septicemia. Chest 1983;83:40-2.
126. 126 Sibbald W, Peters S, Lindsay RM. Serotonin and pulmonary hypertension in human septic ARDS. Crit Care Med 1980;8:490-4.
127. 127 Kasajima K, Ozdemir A, Webb WR, et al. Role of serotonin and serotonin antagonist on pulmonary hemodynamics and microcirculation in hemorrhagic shock. J Thorac Cardiovasc Surg 1974;67:908-14.
128. 128 Vincent JL, Degaute JP, Domb M, et al. Ketanserin, a serotonin antagonist. Administration in patients with acute respiratory failure. Chest 1984;85:510-3.
129. 129 Asherson RA, Oakley C. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol 1986;13:1-5.
130. 130 Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A doppler echocardiographic study of 135 Japanese patients. Chest 1997;111:36-43.
131. 131 Battle RW, Davitt, MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
132. 132 Wiedemann HP, Matthay RA. Pulmonary manifestations of collagen vascular diseases. Clin Chest Med 1989;10:677-723.
133. 133 Marasini B, Biondini ML, Blanchi E, et al. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol 1988;35:419-21.
134. 134 Klimiuk PS, Grennan A, Weinkove C, et al. Platelet serotonin in systemic sclerosis Ann Rheum Dis 1989;48:586-9.
135. 135 Stachow A, Jablonska S, Skiendzielewska A. Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma. Acta Dermal Venereol 1979;59:1-5.
136. 136 Seibold JR, Molony RR, Turkevich D, et al. Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. J Rheumatol 1987; 14:519-24.
137. 137 Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complication portal hypertension, prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100:520-8.
138. 138 Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphological and clinical features. J Am Coll Cardiol 1987;10:1233-8.
139. 139 Voelkel NF. State of the art. Mechanisms of hypoxic pulmonary vasoconstriction. Am Rev Respir Dis 1986;133: 1186-95.
140. 1-receptor mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Pulm Pharmacol 1994;7:65-72.
141. 141 Demiryurek AT, Wadsworth RM, Kane KA, et al. The role of endothelium in hypoxic constriction of human pulmonary artery rings. Am Rev Respir Dis 1993;147:283-90.
142. 142 Rahda TG, Venkitasubramanian TA, Viswanathan R. Effect of acute hypoxia on blood serotonin in human beings and rats. Respiration 1976;33:64-9.
143. 143 Bobrov VA, Fushtei IM, Polivoda SN. Pulmonary hemodynamics and serotonin level in patients with chronic penumonia with arterial hypertension. Vrach Delo 1985;12: 33-5.
144. 144 Pribilova NN. Serotonin metabolism and pulmonary hypertension in chronic lung diseases. Sov Med 1976;12: 107-11.
145. 145 Rostagno O, Prisco D, Boddi M, et al. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991;4:147-51.
146. 146 Zhang X, Ling P. Platelet activation in patients with chronic pulmonary heart disease. Effect of dipyridamole treatment. Chin Med J 1995;108:95-7.
147. 147 Steele P, Ellis JH, Weily HS, et al. Platelet survival time in patients with hypoxemia and pulmonary hypertension. Circulation 1977;55:660-1.
148. 148 Segall M, Goetzman B. Hypoxic pulmonary hypertension: changes in platelet size and number. Am J Perinatol 1991;8: 300-3.
149. 149 Nenci GG, Berretini M, Todisco T, et al. Exhausted platelets in chronic obstructive pulmonary disease. Respiration 1983;44:71-6.
150. 150 Nenci GG, Berretini M, Todisco T, et al. Effects of dipyridamole on the hypoxemic pulmonary hypertension of patients with chronic obstructive pulmonary disease. Respiration 1988;53:13-9.
151. 151 Ran PX, Duan SF. The effects of persantine on pulmonary artery pressure of rats exposed to hypoxia. Chinese J Tuberc Respir Dis 1993;16:216-7, 252-3.
152. 152 Keith IM, Will JA, Huxtable RJ, et al. Anti-platelet agents reduce morphological changes of chronic hypoxic pulmonary hypertension. Histol Histopathol 1987;2:203-6.
153. 153 Herve P, Drouet L, Dosquet C, et al. Primary pulmonary hypertension in a patient with familial platelet storage pool disease: role of serotonin. Am J Med 1990;89:117-20.
154. 154 Sato K, Webb S, Tucker A, et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992;145:793-7.
155. 155 Janakidevi K, Tiruppathi C, del Vecchio PJ, et al. Growth characteristics of pulmonary artery smooth muscle cells from fawn-hooded rats. Am J Physiol 1995;268:L465-70.
156. 156 Ashmore RC, Rodman DM, Sato K, et al. Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. Am J Physiol 1991;260:929-34.
157. 157 Hilliker K, Bell TG, Roth RA. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storeage pool deficiency: 5-hydroxytryptamine uptake by isolated perfused lungs. Thromb Haemost 1983;50:844-7.
158. 158 Stelzner T, Hofmann TA, Brown D, et al. Genetic determinants of pulmonary hypertension in fawn-hooded rats. Chest 1997;111:96S.
159. 159 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984;64:1-12.
160. 160 Reisner SA, Rinkevich D, Markeiwicz W, et al. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992;93:498-504.
161. 161 Moore A, Nachman RL. Platelet Fc receptor: increased expression in myeloproliferative disease. J Clin Invest 1981; 67:1064.
162. 162 Gralnick HR, Vail M, McKeown LP, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;91:697-702.
163. 163 Heller PG, Grinberg AR, Lencioni M, et al. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest 1992;102:642-3.
164. 164 Spencer A. Paroxysmal nocturnal haemoglobinuria in pregnancy: a case report. Br J Obstet Gynecol 1980;87:246-8.
165. 165 Auger WR, Permpikul P, Moser KM. Lupus anticoagulant, heparin use, and thrombocytopenin in patients with chronic thromboembolic pulmonary hypertension. A preliminary report. Am J Med 1995;99:392-6.
166. 166 Hillderdal G. The lung physician and the antiphospholipid syndrome. Eur Respir J 1997;10:511-2.
167. 167 Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996;75:155-41.
168. 168 Schafer AI, Kroll MH, Nonatheromatous arterial thrombosis. Annu Rev Med 1993;144:155-70.
169. 169 Segall ML, Goetzman BW, Schick JB. Thrombocytopenia and pulmonary hypertension in perinatal aspiration syndrome. J Pediatr 1980;96:727-30.
170. 170 Horgan MJ, Carrasco NJM, Risemberg H. The relationship of thrombocytopenia to the onset of persistent pulmonary hypertension of the newborn in the meconium aspiration syndrome. NY State J Med 1985;85:245-7.
171. 171 McGoon MD, Vliestra RE. Vasodilator therapy for primary pulmonary hypertension. Mayo Clin Proc 1984;59: 672-7.
172. 2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. Int J Cardiol 1987;14:303-9.
173. 173 Van der Starre PJ, Reneman RS. The role of serotonin blockers in cardiac anesthesia. J Cardiothorac Vasc Anesth 1994;8:455-62.
174. 174 Van der Starre PJ, Feld RJ, Reneman RS. Ketanserin in the treatment of pulmonary hypertension after valvular surgery: a comparison with nitroprusside. Crit Care Med 1989;17:613-8.
175. 175 Radermacher P, Huet Y, Pluskwa F, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology 1988;68:152-7.
176. 176 Hamet A, Kral B, Cernohorsky D. Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension. Cor et Vasa 1985;27:406-11.
177. 177 Huval WV, Lelcuk S, Feingold H, et al. Effects of nitroprusside and ketanserin upon pulmonary edema after acid injury. Surg Gynecol Obstet 1988;166:527-34.
178. 2 receptor in the mouse. J Pharmacol Exp Ther 1994;268:104-9.
179. 179 Svartholm E, Bergqvist D, Lindblad B, et al. Pulmonary vascular response to live Escherichia coli: influences of different antiplatelet substances. Circ Shock 1987;22:173-83.
180. 180 Deming RH, Wong C, Fox R, et al. Relationship of increased lung serotonin levels to endotoxin-induced pulmonary hypertension in sheep. Effect of a serotonin antagonist. Am Rev Respir Dis 1985;132:1257-61.
181. 181 Olson NC. Role of 5-hydroxytryptamine in endotoxin-induced respiratory failure of pigs. Am Rev Respir Dis 1987; 135:93-9.
182. 182 Desmecht D, Linden A, Amory H, et al. Hemodynamic responses to Pasteurella haemolytica inoculation in calves given type 2 serotonergic antagonist. Can J Physiol Pharmacol 1996;74:572-9.
183. 183 Takeda J, Masuda J, Fukushima K. Droperidol prevents serotonin-induced bronchospasm, pulmonary hypertension, and intrapulmonary shunt. Anesth Analg 1992;74: 316.
184. 2 receptor blockade by ketanserin. J Cardiovasc Pharmacol 1985;7(Suppl 7):S64-6.
185. 185 McCann UD, Seiden LS, Rubin LJ, et al. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. JAMA 1997;52:563-7.
186. 186 Colman KW, Hirsh J, Marder VJ, et al, eds. Hacmostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott, 1994.